R-002 v1.0 | 2026-10-11 TREM2: metabolic rescue, vascular trade-offs and the limits of activation AI-assisted targeted evidence review; not peer reviewed QUESTION Which TREM2-related leads from the connection explorer merit further investigation, and which claims are weakened by conflicting evidence? DECISION Prioritize explaining context-dependent benefit and harm. Do not advance a general claim that increasing TREM2 treats dementia. Both selected connections already have direct literature outside the explorer's bounded sample. SELECTION Two closely related leads were chosen for biological specificity, availability of primary experiments and relevance to safety: TREM2–microglial metabolism and TREM2–vascular pathology. This is an editorial research priority, not a validated ranking by discovery potential. Other leads remain unevaluated. 1. Metabolic rescue without downstream harm There is experimental support for a TREM2–metabolism connection. That connection is already known. Improved energy metabolism or target engagement cannot be treated as a surrogate for cognitive benefit. Support: S1, S2, S3 Challenges: S6, S7, S8 Under which genotype, disease stage and cellular state does a TREM2-related metabolic improvement coincide with neuronal protection, without worsening tau-related or inflammatory outcomes? Build a full-text matrix separating knockout, risk variant, overexpression and antibody agonism. Extract genotype, model, sex, age, timing, biological replicate counts, metabolic measures, neuronal endpoints and adverse findings. Compare compatible experiments before attempting a pooled effect. Deprioritize the therapeutic interpretation if independent models show metabolic improvement without neuronal benefit, or alongside reproducible worsening of tau or inflammatory outcomes. A robust null result must remain in the matrix. 2. Vascular benefit versus amyloid redistribution A vascular injury model supports further mechanistic work, while a CAA model shows a trade-off between vascular and total amyloid. These are different models and interventions, not a clean replication dispute. The clinical MRI signal raises a question; it does not establish that the mouse trade-off caused it. Support: S4 Challenges: S5, S8 Can an intervention preserve neurovascular function without shifting pathology toward vessel-wall amyloid, leakage or hemorrhagic injury? Separate hypoperfusion, vessel-wall amyloid and mixed Alzheimer pathology. Extract vascular and parenchymal measures independently, alongside cognition, neuronal injury and safety outcomes. Seek human imaging/pathology evidence before translating a mouse mechanism. Deprioritize an intervention if neuronal or cognitive readouts improve while independently replicated vascular injury worsens. Reject a proposed cross-model explanation when comparable measurements do not support it. TRIAL Week-96 change in CDR-SB: least-squares mean difference versus placebo (95% CI) 15 mg/kg: -0.31 (-1.61 to 0.98) 40 mg/kg: 0.13 (-1.18 to 1.43) 60 mg/kg: -0.17 (-1.49 to 1.15) All intervals include zero; the primary endpoint was not met. These estimates concern this trial, not a pooled estimate for TREM2 biology. EVIDENCE S1 Ulland et al., Cell (2017) TREM2 Maintains Microglial Metabolic Fitness in Alzheimer's Disease https://pmc.ncbi.nlm.nih.gov/articles/PMC5573224/ Mouse disease models, myeloid-cell experiments and human tissue observations TREM2 deficiency was linked to impaired energy metabolism and mTOR signaling. Metabolic support restored some microglial responses and reduced plaque-adjacent neuronal injury in a deficient amyloid mouse model. Rescue in a TREM2-deficient model is not evidence that boosting an intact pathway improves cognition in people. Tissue observations and experimental interventions answer different questions. Access: Abstract and relevant full-text results S2 Piers et al., FASEB Journal (2020; online 2019) A locked immunometabolic switch underlies TREM2 R47H loss of function in human iPSC-derived microglia https://pubmed.ncbi.nlm.nih.gov/31907987/ Human induced-pluripotent-stem-cell-derived microglia TREM2 variant cells showed reduced mitochondrial respiratory capacity and impaired metabolic switching. Modulating implicated signaling pathways improved cellular metabolic and phagocytic functions. Human-derived cells are not a human treatment trial. Donor replication, culture conditions and the connection between cellular rescue and clinical function require separate assessment. Access: Indexed abstract and publisher metadata S3 Feiten et al., Nature Communications (2026) TREM2 expression level is critical for microglial state, metabolic capacity and efficacy of TREM2 agonism https://www.nature.com/articles/s41467-026-68706-8 TREM2 reporter mice, isolated microglia and chronic antibody treatment TREM2 expression tracked metabolic and lipid-related cellular signatures. Antibody responsiveness depended on the expression range of microglia. This suggests a context variable worth measuring; it does not establish a clinically effective dose, patient subgroup or therapeutic window. Access: Publisher abstract and publication metadata S4 Wang et al., Neural Plasticity (2020) TREM2 Overexpression Attenuates Cognitive Deficits in Experimental Models of Vascular Dementia https://pmc.ncbi.nlm.nih.gov/articles/PMC7306072/ Young adult male mice after transient bilateral carotid occlusion; three treatment groups of 10 TREM2 overexpression improved spatial-learning readouts and reduced hippocampal neuronal loss in this experimental injury model. Small, male-only groups and an experimentally induced injury limit generalization to aging human vascular dementia. Gene overexpression is not interchangeable with antibody agonism. The study reports random group allocation and blinding for specified procedures, not a completed independent bias assessment. Access: Abstract, methods and relevant results S5 Loss of TREM2 / Tg-SwDI study, Alzheimer's & Dementia (2024) Loss of TREM2 diminishes CAA despite an overall increase of amyloid load in Tg-SwDI mice https://pubmed.ncbi.nlm.nih.gov/39308178/ CAA-prone transgenic mice with different Trem2 genotypes, assessed at 16 months Trem2 loss reduced vascular amyloid deposition while increasing overall brain amyloid burden. Vascular and parenchymal outcomes therefore moved in different directions. A lifelong knockout is not the reverse of a drug intervention. This model does not prove that TREM2 stimulation causes vascular harm in humans, but it makes separate vascular endpoints necessary. Access: Indexed abstract and figure descriptions S6 Jain et al., Journal of Experimental Medicine (2023; online 2022) Chronic TREM2 activation exacerbates Aβ-associated tau seeding and spreading https://pmc.ncbi.nlm.nih.gov/articles/PMC9559604/ Amyloid-bearing 5XFAD mice seeded with human Alzheimer-derived tau; chronic agonist antibody Chronic TREM2 stimulation worsened tau seeding and spreading in this experimental context. This challenges blanket benefit from activation, not every TREM2 intervention. The artificial seeding model, intervention timing and antibody mechanism must be distinguished from sporadic human disease. Access: Abstract and relevant experimental results S7 Etxeberria et al., Journal of Neuroscience (2024) Neutral or Detrimental Effects of TREM2 Agonist Antibodies in Preclinical Models of Alzheimer's Disease and Multiple Sclerosis https://pmc.ncbi.nlm.nih.gov/articles/PMC11255434/ Several agonist antibodies across mouse amyloid/tau and demyelination models The tested antibodies had limited effects on Alzheimer-related pathology and disrupted recovery in demyelination models despite evidence of receptor activity. Demyelination findings are a safety-context signal, not direct evidence of harm in human dementia. Antibody format, CNS exposure and timing may explain differences between experiments; those explanations remain hypotheses. Access: Abstract and relevant results/discussion S8 Mummery et al., Nature Medicine (2026) The TREM2 agonistic antibody AL002 in early Alzheimer's disease: a phase 2 randomized trial https://www.nature.com/articles/s41591-026-04273-1 Randomized, double-blind, placebo-controlled trial; 381 participants with early Alzheimer's disease AL002 engaged its target but did not meet the primary CDR-SB endpoint. All three reported week-96 treatment-placebo confidence intervals crossed zero. MRI changes resembling ARIA were the most frequent treatment-emergent adverse events reported in the abstract. A negative trial weakens efficacy claims for AL002 in this population and regimen; it does not prove that every TREM2 strategy must fail. Funded by Alector, with author employment/equity disclosures. The abstract alone cannot support a full safety or risk-of-bias assessment. Access: Publisher abstract, public figure descriptions and disclosures; subscription full text not reviewed NEXT STEPS 01 · Evidence extraction A study-by-study table with exact comparison groups, biological sample sizes, outcomes, effect estimates, uncertainty, allocation/blinding and funding. Retrieve missing full texts and supplements first. Do not grade a study as low risk of bias or pool estimates while required design details remain unverified. 02 · Explain disagreements A context matrix: amyloid-only versus amyloid-plus-tau versus vascular injury; loss of function versus activation; early versus later intervention. Mark observations separately from proposed explanations. Do not resolve differences by counting positive and negative papers. Give clinical endpoints more weight for claims about clinical benefit. 03 · Independent validation plan A prespecified question with one primary outcome, matched controls, biological replication, handling of multiple comparisons and explicit stopping criteria. Identify an independent dataset or qualified experimental collaborator. Proceed only after access, expertise and a suitable design are established. No new dataset analysis or experiment has been executed by MNEME for this report. METHOD searchedOn: 2026-10-11 scope: Targeted narrative review of eight selected primary publications; not a systematic review, meta-analysis or completed risk-of-bias assessment. sources: Primary publisher pages and PubMed/PMC records located by web search and reference follow-up. Evidence was summarized at the access depth shown for each study. queries: TREM2 microglia vascular blood brain barrier Alzheimer study protective detrimental TREM2 microglia mitochondria Alzheimer metabolic function study AL002 INVOKE-2 phase 2 results TREM2 2026 Nature Medicine randomized trial TREM2 deficiency attenuates neuroinflammation protects neurodegeneration tauopathy 2017 Leyns TREM2 cerebral amyloid angiopathy deficiency vascular amyloid study Chronic TREM2 activation exacerbates tau seeding spreading 2023 Neutral or detrimental effects of TREM2 agonist antibodies TREM2 Overexpression Attenuates Cognitive Deficits retracted A locked immunometabolic switch 2020 Piers inclusion: Primary experimental work directly relevant to the two selected mechanisms, plus the randomized clinical trial. Included support, neutral results and adverse findings. Landmark work before the automated scanner's 2020 cutoff was eligible. limitations: Purposive selection can miss studies and introduces selection bias. Search-result dates can be unreliable; publication metadata was preferred. No exhaustive screening denominator, formal certainty score, participant-level reanalysis, effect-size pooling or independent expert review is claimed. Full texts and supplements were not comprehensively extracted. Search results alone do not establish absence of corrections or retractions. noveltyCorrection: The explorer's missing direct edges reflected its narrow corpus and sentence rule. Direct TREM2–metabolism and TREM2–vascular studies were found. These broad connections must not be advertised as MNEME discoveries. maintenance: This dated editorial report is separate from daily automated scans. New records do not silently rewrite its conclusions; a substantive revision requires a new version and an explicit evidence review.